Characteristics of the training and validation cohorts
| Characteristics . | Training cohort (n = 646) . | Validation cohort (n = 646) . | P . |
|---|---|---|---|
| Karnofsky, median (range) | 90 (30-100) | 90 (30-100) | .95 |
| Diagnosis | |||
| AA | 36 | 38 | .98 |
| AML | 193 | 201 | |
| ALL | 96 | 99 | |
| MPD | 164 | 153 | |
| LPD | 93 | 94 | |
| MDS | 53 | 53 | |
| Other | 11 | 8 | |
| Disease phase | |||
| CR | 433 | 449 | .34 |
| Non-CR | 213 | 197 | |
| Year | |||
| 1990-1999 | 183 | 189 | .50 |
| 2000-2009 | 255 | 235 | |
| 2010-2016 | 208 | 222 | |
| Median recipient age, median (range) | 40 (9-71) | 41 (14-74) | .53 |
| Median donor age, median (range) | 35 (0-69) | 35 (0-73) | .97 |
| Recipient sex | |||
| M | 365 | 386 | .24 |
| F | 281 | 260 | |
| Donor sex | |||
| M | 368 | 376 | .65 |
| F | 278 | 270 | |
| HLA-Match | |||
| Full match | 426 | 431 | .82 |
| 1 Ag Mismatch | 75 | 68 | |
| Haplo | 145 | 147 | |
| Relation | |||
| Unrelated | 464 | 490 | .10 |
| Related | 182 | 156 | |
| Conditioning | |||
| MAC | 418 | 440 | .19 |
| RIC | 228 | 206 | |
| Stem cell source | |||
| BM | 434 | 475 | .05 |
| PB | 168 | 147 | |
| CB | 44 | 24 | |
| Median dose*108/Kg, median (range) | 4.12 (0.04-25.8) | 4.05 (0.07-26.4) | .57 |
| GVHD prophylaxis | |||
| CSA+MMF | 174 | 157 | .3 |
| CSA+MTX | 468 | 483 | |
| Missing | 4 | 6 | |
| T-cell depletion | |||
| ATG y/n | 220 | 207 | .8 |
| Cy-post SCT | 123 | 128 | |
| None | 298 | 304 | |
| Missing | 5 | 7 | |
| aGVHD grade II-IV, n (%) | 188 (26) | 174 (29) | .4 |
| cGVHD moderate/severe, n (%) | 144 (22) | 148 (23) | .7 |
| Outcomes (%) | |||
| 5-y OS | 59 | 60 | .87 |
| 5-y TRM | 15 | 16 | .30 |
| 5-y DFS | 46 | 47 | .75 |
| Characteristics . | Training cohort (n = 646) . | Validation cohort (n = 646) . | P . |
|---|---|---|---|
| Karnofsky, median (range) | 90 (30-100) | 90 (30-100) | .95 |
| Diagnosis | |||
| AA | 36 | 38 | .98 |
| AML | 193 | 201 | |
| ALL | 96 | 99 | |
| MPD | 164 | 153 | |
| LPD | 93 | 94 | |
| MDS | 53 | 53 | |
| Other | 11 | 8 | |
| Disease phase | |||
| CR | 433 | 449 | .34 |
| Non-CR | 213 | 197 | |
| Year | |||
| 1990-1999 | 183 | 189 | .50 |
| 2000-2009 | 255 | 235 | |
| 2010-2016 | 208 | 222 | |
| Median recipient age, median (range) | 40 (9-71) | 41 (14-74) | .53 |
| Median donor age, median (range) | 35 (0-69) | 35 (0-73) | .97 |
| Recipient sex | |||
| M | 365 | 386 | .24 |
| F | 281 | 260 | |
| Donor sex | |||
| M | 368 | 376 | .65 |
| F | 278 | 270 | |
| HLA-Match | |||
| Full match | 426 | 431 | .82 |
| 1 Ag Mismatch | 75 | 68 | |
| Haplo | 145 | 147 | |
| Relation | |||
| Unrelated | 464 | 490 | .10 |
| Related | 182 | 156 | |
| Conditioning | |||
| MAC | 418 | 440 | .19 |
| RIC | 228 | 206 | |
| Stem cell source | |||
| BM | 434 | 475 | .05 |
| PB | 168 | 147 | |
| CB | 44 | 24 | |
| Median dose*108/Kg, median (range) | 4.12 (0.04-25.8) | 4.05 (0.07-26.4) | .57 |
| GVHD prophylaxis | |||
| CSA+MMF | 174 | 157 | .3 |
| CSA+MTX | 468 | 483 | |
| Missing | 4 | 6 | |
| T-cell depletion | |||
| ATG y/n | 220 | 207 | .8 |
| Cy-post SCT | 123 | 128 | |
| None | 298 | 304 | |
| Missing | 5 | 7 | |
| aGVHD grade II-IV, n (%) | 188 (26) | 174 (29) | .4 |
| cGVHD moderate/severe, n (%) | 144 (22) | 148 (23) | .7 |
| Outcomes (%) | |||
| 5-y OS | 59 | 60 | .87 |
| 5-y TRM | 15 | 16 | .30 |
| 5-y DFS | 46 | 47 | .75 |
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte globulins; CB, cord blood; CR, complete response; CSA, cyclosporine A; Cy-post, cychophosphamide post-transplant; F, female; LPD, lymphoproliferative disease other than ALL; M, male; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MMF, mycophenolate; MPD, myeloproliferative disease; MTX, methotrexate; non-CR, other than CR; RIC, reduced intensity conditioning.